Latin America Cutaneous Oncology Management (LACOM) I: The Role of Skin Care in Oncology Patients and Survivors.

IF 1.5 4区医学 Q3 DERMATOLOGY

Journal of Drugs in Dermatology Pub Date : 2025-03-01 DOI:10.36849/JDD.8565

Daniel Alcalá Pérez, Ana Sofia Acosta Madiedo, Sebastian Andreani, Anneke Andriessen, Hebert Cárdenas, Marcela Moreno, Daniel Motola Kuba, Julia Riganti, José Enrique Ollague, Mario Lacouture, Alejandra Toquica

{"title":"Latin America Cutaneous Oncology Management (LACOM) I: The Role of Skin Care in Oncology Patients and Survivors.","authors":"Daniel Alcalá Pérez, Ana Sofia Acosta Madiedo, Sebastian Andreani, Anneke Andriessen, Hebert Cárdenas, Marcela Moreno, Daniel Motola Kuba, Julia Riganti, José Enrique Ollague, Mario Lacouture, Alejandra Toquica","doi":"10.36849/JDD.8565","DOIUrl":null,"url":null,"abstract":"Background: Cancer-treatment-related cutaneous adverse events (cAEs) are common and may severely impact quality of life (QoL) and decrease treatment outcomes. The Latin American Cutaneous Oncology Management (LACOM) project provides clinical insights into cancer-treatment-related cAEs, offering tools for preventing and managing cAEs.Methods: LACOM I focuses on integrating education, prophylactic measures, and skincare in cancer treatment to improve treatment adherence, outcomes, and patients' and survivors' QoL.Results: The LACOM panel provides evidence and opinion-based best practice recommendations for oncology skincare programs to support all stakeholders in the Latin American healthcare setting (Argentina, Chili, Colombia, Ecuador, Panama, Peru, and Mexico) working with oncology patients throughout the entire continuum of care to achieve optimal outcomes, improving cancer patients and survivors' QoL. Oncology skincare programs comprise hygiene, moisturization, and sun protection with products that should be safe and help to minimize cAEs and improve skin conditions.Conclusions: Integrating education, general measures, and skincare programs into cancer treatment should encourage the adoption of a proactive role of skincare from the beginning of treatment and ongoing, supporting optimal outcomes and improving cancer patients' and survivors' QoL. J Drugs Dermatol. 2025;24(3):262-268. doi:10.36849/JDD.8565.","PeriodicalId":15566,"journal":{"name":"Journal of Drugs in Dermatology","volume":"24 3","pages":"262-268"},"PeriodicalIF":1.5000,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Drugs in Dermatology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.36849/JDD.8565","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"DERMATOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Background: Cancer-treatment-related cutaneous adverse events (cAEs) are common and may severely impact quality of life (QoL) and decrease treatment outcomes. The Latin American Cutaneous Oncology Management (LACOM) project provides clinical insights into cancer-treatment-related cAEs, offering tools for preventing and managing cAEs.

Methods: LACOM I focuses on integrating education, prophylactic measures, and skincare in cancer treatment to improve treatment adherence, outcomes, and patients' and survivors' QoL.

Results: The LACOM panel provides evidence and opinion-based best practice recommendations for oncology skincare programs to support all stakeholders in the Latin American healthcare setting (Argentina, Chili, Colombia, Ecuador, Panama, Peru, and Mexico) working with oncology patients throughout the entire continuum of care to achieve optimal outcomes, improving cancer patients and survivors' QoL. Oncology skincare programs comprise hygiene, moisturization, and sun protection with products that should be safe and help to minimize cAEs and improve skin conditions.

Conclusions: Integrating education, general measures, and skincare programs into cancer treatment should encourage the adoption of a proactive role of skincare from the beginning of treatment and ongoing, supporting optimal outcomes and improving cancer patients' and survivors' QoL. J Drugs Dermatol. 2025;24(3):262-268. doi:10.36849/JDD.8565.

查看原文本刊更多论文

拉丁美洲皮肤肿瘤管理（LACOM） I：皮肤护理在肿瘤患者和幸存者中的作用。

背景：癌症治疗相关的皮肤不良事件（cAEs）是常见的，并可能严重影响生活质量（QoL）和降低治疗结果。拉丁美洲皮肤肿瘤管理（LACOM）项目提供了与癌症治疗相关的cAEs的临床见解，提供了预防和管理cAEs的工具。方法：LACOM I的重点是将教育，预防措施和皮肤护理与癌症治疗相结合，以提高治疗依从性，结果以及患者和幸存者的生活质量。结果：LACOM专家组为肿瘤皮肤护理项目提供了基于证据和意见的最佳实践建议，以支持拉丁美洲医疗保健环境（阿根廷、智利、哥伦比亚、厄瓜多尔、巴拿马、秘鲁和墨西哥）的所有利益相关者在整个连续护理过程中与肿瘤患者合作，以达到最佳结果，改善癌症患者和幸存者的生活质量。肿瘤皮肤护理项目包括卫生、保湿和防晒产品，这些产品应该是安全的，并有助于减少cae和改善皮肤状况。结论：将教育、一般措施和护肤方案整合到癌症治疗中，可以鼓励从治疗开始到治疗过程中采取积极的护肤作用，支持最佳结果，改善癌症患者和幸存者的生活质量。皮肤医学杂志，2025;24(3):262-268。doi: 10.36849 / JDD.8565。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Journal of Drugs in Dermatology DERMATOLOGY-

CiteScore

2.20

自引率

13.30%

发文量

289

审稿时长

3-6 weeks

期刊介绍： The Journal of Drugs in Dermatology (JDD) is a peer-reviewed publication indexed with MEDLINE®/PubMed® that was founded by the renowned Dr. Perry Robins MD. Founded in 2002, it offers one of the fastest routes to disseminate dermatologic information and is considered the fastest growing publication in dermatology. We present original articles, award-winning case reports, and timely features pertaining to new methods, techniques, drug therapy, and devices in dermatology that provide readers with peer reviewed content of the utmost quality. Our high standards of content are maintained through a balanced, peer-review process. Articles are reviewed by an International Editorial Board of over 160 renowned experts.